The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...

Analysts were effusive about Merus’ new HNSCC data, writing that petosemtamab could “become the standard of care” in the ...

Gilead Sciences (NASDAQ:GILD) announced Friday that its antibody-drug conjugate Trodelvy reached the main goal compared to ...